Table 3.
Treatment received and outcomes.
| Stage | Number of patients (percentage) | Median overall survival (mOS) | Range of survival |
|---|---|---|---|
| Stage I | n = 0 | 0 | 0 |
|
| |||
| Stage II | n = 6 | 43 m | 18–60 m |
|
| |||
| Stage III | n = 14 | 12.5 m | 6–30 m |
|
| |||
| Stage II and stage III | n = 20; (46.5%) | ||
| (1) Upfront surgery | n = 12 | 19.75 m | 6–60 m |
| (THE/TTE +/− Cth) | |||
| (2) NACT + surgery | n = 2 | 16 m | 14–18 m |
| (3) Cth/LAR; no Surgery | n = 6 | 8.75 m | 6–13 m |
|
| |||
| Stage IV | n = 23; (53.5%) | ||
| (1) Cisplatin + etoposide (G3) | n = 21 | 6.5 m | 1.5–32 m |
| (2) Octreotide LAR (G2) | n = 2 | 16 m | |